SNORD113-2: A promising drug target and biomarker for small nucleolar RNA (snRNA)

Target Name: SNORD113-2

NCBI ID: G767562

SNORD113-2

Other Name(s): small nucleolar RNA, C/D box 113-2 | 14q(I-2) | Small nucleolar RNA, C/D box 113-2

SNORD113-2: A promising drug target and biomarker for small nucleolar RNA (snRNA)

Introduction

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. One of the key functions of snRNA is to interact with other snRNAs and proteins to help maintain the stability and composition of the nucleolar organelle. C/D box 113-2, a specific snRNA molecule, has been identified as a potential drug target and biomarker due to its unique structure and function.

Structure and function of C/D box 113-2

C/D box 113-2 is a 24 nucleotide long RNA molecule that contains a highly conserved head domain with a single RNA binding protein (RBP) domain and a unique C-terminal region that includes a fMet/CBF domain and a G-rich repeat. The fMet/CBF domain is a conserved protein-coding domain that is involved in the regulation of RNA stability and localization, while the G-rich repeat is a unique structural feature that is involved in the formation of a specific RNA structure.

In addition to its conserved structural features, C/D box 113-2 has been shown to play a unique function in the regulation of gene expression. studies have shown that overexpression of C/D box 113-2 can lead to the accumulation of snRNA in the nucleolar organelle, and that this accumulation can alter the stability and composition of the nucleolar organelle. Furthermore, studies have also shown that C/D box 113-2 can interact with other snRNAs and proteins to help maintain the stability and composition of the nucleolar organelle.

Drug targeting potential

The unique structure and function of C/D box 113-2 make it an attractive drug target. One of the main advantages of this target is its high stability, which allows for the potential of using small molecules to inhibit its function without having a significant impact on the stability of the nucleolar organelle. Additionally, the fact that C/D box 113-2 is located in the nucleolar organelle, which is a highly enriched organelle with a large number of potential drug targets, makes it an even more attractive target.

Another potential strategy for targeting C/D box 113-2 is to use RNA interference (RNAi) technology. RNAi allows for the specific and targeted destruction of mRNAs, and can be used to knockdown the expression of a specific gene, including C/D box 113-2. This approach can be used to study the role of C/D box 113-2 in gene expression and to identify potential drug targets.

Biomarker potential

C/D box 113-2 has also been shown to be a potential biomarker for a variety of diseases, including cancer. The unique structure and function of this snRNA molecule make it an attractive candidate for use as a biomarker. For example, C/ D box 113-2 has been shown to be overexpressed in a variety of cancer tissues, and may be a useful biomarker for the diagnosis and treatment of cancer.

In addition to its potential as a biomarker, C/D box 113-2 has also been shown to be involved in the regulation of cell apoptosis, which is a critical process that helps maintain tissue homeostasis and contributes to the development and progression of many diseases . Therefore, C/D box 113-2 may also be a useful biomarker for the diagnosis and treatment of certain diseases.

Conclusion

C/D box 113-2 is a unique and promising snRNA molecule that has the potential to be a drug target and biomarker. Its unique structure and function make it an attractive target for small molecules, RNA interference

Protein Name: Small Nucleolar RNA, C/D Box 113-2

The "SNORD113-2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD113-2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets